List view / Grid view
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
Novel vaccine technologies are critical to improving the public health response to infectious disease threats that continually emerge and re-emerge, according to scientists at the NIAID...
Results from two Phase 1 clinical trials show an experimental Zika vaccine is safe and induces an immune response in healthy adults.
Research published in The Journal of Experimental Medicine suggests potential treatment for glioblastoma
20 June 2016 | By Victoria White, Digital Content Producer
Inovio and GeneOne Life Science have received approval to initiate a Phase I human trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700)...
